Dr. Reddy’s delays semaglutide supplies over quality issues, causing shares to drop amid ongoing investigations and commitment to product safety.

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient…

Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.